Agenus Inc. Reports 2025 Financial Results and Progress on BOT+BAL Program

Agenus Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The company highlighted significant progress in its botensilimab (BOT) plus balstilimab (BAL) immunotherapy program. Early access programs for BOT+BAL have expanded globally, generating approximately $4.2 million in initial revenue from over 200 physician inquiries across more than 30 countries. The program has also seen advancements in clinical development, with the BOT+BAL combination showing promising results in refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC), including a 42% two-year overall survival rate. The Phase 3 BATTMAN registrational trial for MSS mCRC is now underway. France has expanded reimbursed access for BOT+BAL to include ovarian cancer and sarcomas. Additionally, a strategic collaboration with Zydus has strengthened Agenus's balance sheet and secured manufacturing capacity for BOT+BAL development and commercialization. The company reported a net loss of $(3.1) million for the full year 2025.